Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Selection Phase 1 Study Evaluating the Safety and Tolerability of Silmitasertib

NCT05817708 is registered in ClinicalTrials.gov with Senhwa Biosciences, Inc. as lead sponsor.

NCT NCT05817708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05817708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Selection Phase 1 Study Evaluating the Safety and Tolerability of Silmitasertib
Lead sponsor
Senhwa Biosciences, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 28, 2022
Completion date
June 20, 2023
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19